Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34
datasets available to search
ShareScore release 0.9.0
Dataset results
34 results for “Cerebral venous thrombosis”
A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)
ClinicalTrials.gov study NCT02913326. IPD Sharing: Not stated. Countries: 9. Publications: 4.
Data from: Trends in incidence and epidemiological characteristics of cerebral venous thrombosis in the United States
Objective To test the hypothesis that racial-, age- and sex-specific incidence of cerebral venous thrombosis (CVT) has increased in the United States over the last decade. Methods In this retrospective cohort study, validated International Classification of Disease codes were used to identify all new cases of CVT (n=5,567) in the State Inpatients Database (SID) of New York and Florida (2006-2016). A new CVT case was defined as first hospitalization for CVT in the SID without prior CVT hospitalization. CVT counts were combined with annual Census data to compute incidence. Joinpoint regression was used to evaluate trends in incidence over time. Results From 2006-2016, annual age and sex-standardized incidence of CVT in cases/million population ranged from 13.9-20.2, but incidence varied significantly by sex (females: 20.3-26.9; males 6.8-16.8) and by age/sex (females 18-44yo: 24.0-32.6%; males: 18-44yo: 5.3-12.8). Incidence also differed by race (Blacks:18.6-27.2; Whites: 14.3-18.5; Asians: 5.1-13.8). On joinpoint regression, incidence increased across 2006-2016 but most of this increase was driven by increase in all age groups of males (combined annualized percentage change (APC) 9.2%, p-value <0.001), females 45-64 yo (APC 7.8%, p-value <0.001) and females ≥65 yo (APC 7.4%, p-value <0.001). Incidence in females 18-44 yo remained unchanged over time. Conclusion: CVT incidence is disproportionately higher in blacks compared to other races. New CVT hospitalizations increased significantly over the last decade mainly in males and older females. Further studies are needed to determine whether this increase represents true increase from changing risk factors or artefactual increase from improved detection.
Direct oral anticoagulants in treatment of cerebral venous thrombosis: systematic review
Objectives Current guidelines do not recommend direct oral anticoagulants (DOAC) to treat cerebral venous thrombosis (CVT) despite their benefits over standard therapy. We performed a systematic review to summarize the published experience of DOAC therapy in CVT. Data sources MEDLINE, EMBASE, and COCHRANE databases up to November 18, 2020. Eligibility criteria All published articles of patients with CVT treated with DOAC were included. Studies without follow-up information were excluded. Data extraction and synthesis Two independent reviewers screened articles and extracted data. A risk of bias analysis was performed. Primary and secondary outcome measures Safety data included mortality, intracranial hemorrhage (ICH), or other adverse events. Efficacy data included recurrent CVT, recanalization rates, and disability by modified Rankin Scales (mRS). Results 33 studies met inclusion criteria. One randomized controlled trial, 5 observational cohorts, and 27 case series or studies reported 279 patients treated with DOAC for CVT: 41% dabigatran, 47% rivaroxaban, 10% apixaban, and 2% edoxaban, in addition to 315 patients treated with standard therapy. The observational cohorts showed a similar risk of death in DOAC and standard therapy arms (RR 2.12, 95%CI 0.29-15.59). New ICH was reported in 2 (0.7%) DOAC-treated patients and recurrent CVT occurred in 4 (1.5%). A favourable mRS between 0 and 2 was reported in 94% of DOAC-treated patients, more likely than standard therapy in observational cohorts (RR 1.13, 95% CI: 1.02-1.25). Conclusion The evidence for DOAC use in CVT is limited although suggests sufficient safety and efficacy despite variability in timing and dose of treatment. This systematic review highlights that further rigorous trials are needed to validate these findings and to determine optimal treatment regimens. PROSPERO ID: CRD42017078398
The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis (CVT)
ClinicalTrials.gov study NCT00924859. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis
ClinicalTrials.gov study NCT06551402. IPD Sharing: NO. Countries: 1. Publications: 2.
Clinical Deterioration in Cerebral Venous Thrombosis: A Predictive Study
ClinicalTrials.gov study NCT06266585. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis
ClinicalTrials.gov study NCT01204333. IPD Sharing: Not stated. Countries: 6. Publications: 6.
The Norwegian Cerebral Venous Thrombosis Study
ClinicalTrials.gov study NCT05021198. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
ClinicalTrials.gov study NCT05990894. IPD Sharing: NO. Countries: 1. Publications: 1.
Global Impact of the COVID 19 Pandemic on Stroke Care, Cerebral Venous Thrombosis, and Subarachnoid Hemorrhage
ClinicalTrials.gov study NCT04934020. IPD Sharing: UNDECIDED. Countries: 1. Publications: 11.
Study of Rivaroxaban for CeREbral Venous Thrombosis
ClinicalTrials.gov study NCT03178864. IPD Sharing: YES. Countries: 1. Publications: 1.
Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam
ClinicalTrials.gov study NCT07083609. IPD Sharing: NO. Countries: 1. Publications: 17.
Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)
ClinicalTrials.gov study NCT05448248. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Clinical and Radiological Correlations
ClinicalTrials.gov study NCT02013635. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Dedicated Venous Sinus Thrombectomy Stent for Endovascular Treatment of Cerebral Venous Sinus Thrombosis.
ClinicalTrials.gov study NCT05291585. IPD Sharing: Not stated. Countries: 1. Publications: 6.
The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis
ClinicalTrials.gov study NCT04269954. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis
ClinicalTrials.gov study NCT06531122. IPD Sharing: NO. Countries: 1. Publications: 2.
Dabigatran Versus Apixaban in Cerebral Venous Thrombosis
ClinicalTrials.gov study NCT06551415. IPD Sharing: NO. Countries: 1. Publications: 2.
Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
ClinicalTrials.gov study NCT04660747. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Prediction of Cerebral Venous Thrombosis with a new clinical score and D-dimer levels
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.